REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
23/03/2026
Voltar para busca
Dado oficial do USPTO
NEOSENTIA NIPD GENETICS LIQUID BIOPSY CANCER
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
24/03/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 42, 44
Data de depósito
08/06/2020
Data de registro
23/03/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/03/2021
Última transação
24/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
84
Localização do titular
CY
Examinador
SAUNDERS, ANDREA DAWN
Unidade examinadora
M80
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the stylized wording "NIPD GENETICS" in gray above "NEOSENTIA" with "NEO" in red and "SENTIA" in gray, above "LIQUID BIOPSY CANCER" in gray.
Titulares e representantes
Titulares
MEDICOVER PUBLIC CO LTD
NIPD Genetics Public Company Limited
Representantes
Paulo A. de Almeida Patel & Almeida PC
Classificação técnica
Classes Nice
Classe 1Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Kits composed of reagents for genetic testing for medical and scientific research purposes; kits composed of reagents for genetic testing for medical and scientific research purposes in the field of oncology; kits composed of reagents for cancer diagnosis and prognosis for medical and scientific research purposes; kits composed of reagents for testing for chromosomal or mutational abnormalities in cancer patients for medical and scientific research purposes
Classe 42
Medical laboratory services for cancer testing; design and development of medical diagnostic tests and products; medical and scientific research in the field of genetic testing particularly in the field of oncology; providing medical and scientific research information in the field of genetic testing; genetic testing for scientific research and analysis purposes in the field of oncology cancer; genetic engineering services for scientific research purposes
Classe 44
Medical testing services for diagnosis of cancer; medical genetic testing; medical diagnostic testing in the field of oncology; medical testing of blood for diagnosis of genetic abnormalities such as mutations during cancer disease; medical testing for diagnosis of genetic disordersdiseases and syndromes; genetic testing for diagnostic or treatment purposes and genetic counseling in the field of cancer treatment; medical and healthcare services relating to DNAgenetics and genetic testing
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
16/01/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/06/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/06/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/06/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/12/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
29/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
23/09/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
23/09/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
23/09/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
23/09/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
15/08/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
30/06/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
30/06/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
23/06/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
23/03/2021
GPNX
NOTIFICATION PROCESSED BY IB
11/01/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/01/2021
PUBO
PUBLISHED FOR OPPOSITION
05/01/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
23/12/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
23/12/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
16/12/2020
ALIE
ASSIGNED TO LIE
30/11/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/11/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/11/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/11/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/11/2020
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
30/10/2020
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
30/10/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
30/10/2020
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
30/10/2020
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
30/10/2020
RFNT
REFUSAL PROCESSED BY IB
19/10/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/10/2020
RFRR
REFUSAL PROCESSED BY MPU
01/10/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/09/2020
CNRT
NON-FINAL ACTION WRITTEN
10/09/2020
DOCK
ASSIGNED TO EXAMINER
09/09/2020
MAFR
APPLICATION FILING RECEIPT MAILED
21/08/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
17/08/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/08/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace NEOSENTIA NIPD GENETICS LIQUID BIOPSY CANCER ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.